BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33528892)

  • 21. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC.
    Wong AT; To RM; Wong CL; Chan WK; Ma ES
    Diagn Mol Pathol; 2013 Sep; 22(3):138-43. PubMed ID: 23846439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
    Hsiue EH; Lee JH; Lin CC; Yang JC
    Expert Rev Mol Diagn; 2016 Dec; 16(12):1251-1257. PubMed ID: 27737606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
    Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
    Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of the loop-mediated isothermal amplification method and the QIAGEN
    Saito Y; Takahashi N; Matsui A; Michiyuki S; Yamauchi Y; Shimizu Y; Hoshi E; Sakao Y; Kawamura M
    J Thorac Dis; 2021 Feb; 13(2):743-753. PubMed ID: 33717546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.
    Lopez-Rios F; Angulo B; Gomez B; Mair D; Martinez R; Conde E; Shieh F; Tsai J; Vaks J; Current R; Lawrence HJ; Gonzalez de Castro D
    J Clin Pathol; 2013 May; 66(5):381-5. PubMed ID: 23386666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five Technologies for Detecting the
    Chen YL; Lin CC; Yang SC; Chen WL; Chen JR; Hou YH; Lu CC; Chow NH; Su WC; Ho CL
    Front Oncol; 2019; 9():631. PubMed ID: 31380273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
    Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
    Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.
    Nakamura H; Koizumi H; Sakai H; Kimura H; Miyazawa T; Marushima H; Saji H; Takagi M
    Clin Lung Cancer; 2018 Mar; 19(2):170-174. PubMed ID: 29150249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
    Benlloch S; Botero ML; Beltran-Alamillo J; Mayo C; Gimenez-Capitán A; de Aguirre I; Queralt C; Ramirez JL; Ramón y Cajal S; Klughammer B; Schlegel M; Bordogna W; Chen D; Zhang G; Kovach B; Shieh F; Palma JF; Wu L; Lawrence HJ; Taron M
    PLoS One; 2014; 9(2):e89518. PubMed ID: 24586842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
    Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
    EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
    Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
    Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A
    BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
    BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.
    Choo JR; Tan CS; Soo RA
    Target Oncol; 2018 Apr; 13(2):141-156. PubMed ID: 29423594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible False Results With cobas
    Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
    Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.